A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase II Clinical Study to Evaluate the Safety, Tolerability, PK/PD Profile, and Efficacy of Multiple Doses of BGM0504 Injection in Overweight or Obese Subjects Without Diabetes
Latest Information Update: 27 Jun 2025
At a glance
- Drugs BGM 0504 (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Sponsors BrightGene Bio-medical technology
Most Recent Events
- 23 Jun 2025 Accordinfg to BrightGene media release the data from this trial has been presented at the 85th Scientific Conference of the American Diabetes Association (ADA).
- 23 Jun 2025 Results published in the BrightGene media release
- 26 May 2025 New trial record